AEterna Zentaris to Present Preclinical Data for PI3K/Erk 1/2 Inhibitor, AEZS-136, at American Chemical Society National Meeting

QUÉBEC CITY, Aug. 13, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its V.P., Medicinal Chemistry, Matthias Gerlach, PhD, will be making a poster presentation on preclinical results for the Company's novel orally active anticancer PI3K/Erk 1/2 inhibitor, AEZS-136, during the 244th National Meeting of the American Chemistry Society which will be held August 19-23, 2012, in Philadelphia.

Poster #46: "Dual PI3K/Erk Inhibitor AEZS-136, A Potent Anti-Tumor Compound Under Preclinical Development ", M. Gerlach, I. Seipelt, L. Blumenstein, K. Jung, T. Schuster, G. Mueller, E. Guenther, J. Engel and M. Teifel.
Session: General poster session / division of medicinal chemistry;
Dates and time:
Sunday, August 19, 2012 from 7pm to 9pm (Eastern); and
Monday, August 20, 2012 from 8pm to 10pm (Eastern);
Venue: Pennsylvania Convention Center, Hall D

About AEZS-136

AEZS-136 is an integral part of the Company's kinase research program comprising the investigation of different compounds for single Erk inhibition, single PI3K inhibition and dual Erk/PI3K kinase inhibition. AEZS-136 selectively inhibits the kinase activity of Erk 1/2 and class 1 PI3Ks, enabling simultaneous inhibition of the Raf-Mek-Erk and the PI3K-Akt signaling cascades. AEZS-136 was discovered using the Company's proprietary compound library and high throughput screening technology.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For more information please visit


Back to news